

1 **Antimicrobial resistance of bacteria isolates among**
2 **patients with chronic wound infections in Tanga Regional**
3 **Referral Hospital, Tanzania**

4
5 Aleena Dawer^{1,3*}, Victor Msengi², Theresia B. Mtui^{1,2}, Sarah Sarakikya², Rashid Suleiman²,
6 John P. A. Lusingu^{1,3}

7
8 ¹National Institute of Medical Research Tanga Centre, Tanga, Tanzania

9 ²Tanga Regional Referral Hospital, Tanga, Tanzania

10 ³Department of Global Health, Georgetown University, Washington D.C., United States of
11 America

12
13 *Corresponding author

14 Email: amd429@georgetown.edu (AD)

15

16

17

18

19

20

21

22

23

24 **Abstract**

25 **Background:** Bacterial wound infections are the second leading cause of mortality globally,
26 with approximately 50% of contaminated wounds evolving into chronic infections. In
27 Tanzania, this challenge is exacerbated by the over prescription of antibiotics and the
28 emergence of drug-resistant bacteria, compounded by inadequate hospital hygiene and
29 sanitation practices. This study investigated chronic wound infections in Tanga, Tanzania,
30 focusing on antibiotic susceptibility patterns.

31 **Methods:** A cross-sectional, mixed-methods study was conducted at the Tanga Regional
32 Referral Hospital (TRRH) from July 2023 to December 2023. Pus and Culture Sensitivity
33 tests were performed on samples from 89 chronic wound patients to identify bacterial isolates
34 and assess antibiotic susceptibility. Data was analyzed using STATA, Excel, and Python.

35 **Results:** Of 89 patients, 82 (92.1%) had positive bacterial isolates in wound cultures,
36 predominantly with *Staphylococcus aureus*, 24 (29.3%). Surgical-site infections (SSI) were
37 the most prevalent diagnosis, followed by diabetic foot ulcers and septic wounds. Antibiotic
38 resistance analysis revealed a marked trend in multi-drug resistance (MDR), notably against
39 amoxicillin, while meropenem was identified as the most effective antibiotic.

40 **Conclusion:** The elevated rate of MDR at TRRH, particularly against commonly used
41 antibiotics, emphasizes the need for improved antibiotic stewardship and healthcare worker
42 education. It necessitates increased health awareness about effective wound management and
43 the development of robust healthcare strategies to combat the escalating challenge of MDR.

44 **Keywords:**

45 Chronic bacterial wound infections, Antimicrobial resistance, Healthcare-associated
46 Infections

47

48 Introduction

49 Deaths associated with bacterial wound infections rank as the second leading cause of
50 global mortality, according to the Global Burden of Diseases Level 3¹. Alarminglly,
51 approximately 50% of contaminated bacterial wounds transition into clinical infections². The
52 World Health Organization (WHO) identified hospital-acquired infections (HAI) as
53 accounting for 25.1% of all global infections, which were attributed to surgical wounds³.
54 Bacterial pathogens persist as a significant cause of morbidity and mortality worldwide¹,
55 posing a consistent challenge in healthcare settings. In developing nations like Tanzania,
56 bacterial infections pose a grave threat: the incidence of wound infections is estimated to be
57 as high as 40% as compared to the 3-11% recorded in developed countries².

58 More specifically, *Staphylococcus aureus* (*S. aureus*) is a persistent pathogen
59 associated with a wide range of infections, from mild skin infections to severe systemic
60 diseases such as diabetic foot ulcers and osteomyelitis. The prevalence of *S. aureus* is rising
61 in Tanzania, where it contributes significantly to HAI and antibiotic resistance issues⁴. The
62 WHO's 2017 report highlighted *S. aureus* as a priority pathogen, emphasizing the need for
63 focused research and development of new therapeutic options due to its ability to develop
64 resistance across multiple antibiotic classes rapidly, thereby limiting treatment options⁵.

65 Wound infections are highly prevalent in hospitals and often remain chronic due to
66 improper healing. A chronic wound infection refers to a wound that fails to progress through
67 the normal stages of healing, often remaining unhealed for more than three months. These
68 wounds are characterized by persistent inflammation, delayed closure, and a high risk of
69 recurring infections. Socio-economic and biological factors contribute to the prevalence of
70 chronic wound infections, including bacterial resistance to prescribed antibiotics⁶.

71 Antimicrobial resistance (AMR) occurs when bacteria undergo genetic changes that
72 allow them to withstand the effects of antibiotics that were previously effective. When

73 patients are exposed to multiple doses of antibiotics, resistant bacteria survive and multiply,
74 displacing the susceptible strains⁷. This resistance makes standard treatments ineffective,
75 leading to prolonged illness, higher medical expenses, and increased mortality and morbidity.
76 These resistant bacterial strains have spread across the globe due to the microorganism's
77 genetic plasticity and mobility.

78 This resistance is particularly high in developing countries, with underlying problems
79 attributed to economic and societal issues, with effective antimicrobial drugs squandered by
80 excessive use⁸. Ecological studies support the notion that higher antibiotic usage directly
81 influences resistance⁹. This especially realms true in developing countries burdened by
82 bacterial infectious diseases, crowded cities, poor sanitation, and the availability of antibiotics
83 over the counter (OTC) without a prescription. These medications are often self-prescribed
84 through unregulated supply chains¹⁰. Inappropriate antibiotic use, coupled with rapid disease
85 spread through crowding and sexual contact, contributes to higher AMR rates. However,
86 recent data remains difficult to interpret due to poor record-keeping and testing coverage in
87 low- and middle-income countries¹¹. As a result, the absence of laboratory diagnostic
88 facilities has led to the adoption of observational diagnosis in the administration of
89 antimicrobial medications), resulting in unnecessary and excessive treatments¹².

90 In Tanzania, challenges include the easy availability of OTC antibiotics and
91 insufficient healthcare guidance. Commonly used antibiotics in Tanzania, such as amoxicillin
92 (34.8%), metronidazole (15.4%), tetracycline (13.3%), ciprofloxacin (6.0%), and cefalexin
93 (4.5%), are becoming increasingly less effective due to their widespread use¹³. Moreover,
94 antibiotic consumption is predicted to increase by 13-fold over the next twelve years in
95 Tanzania, signaling an urgent need for action¹³.

96 With escalating post-operative complications and increasing antibiotic resistance in
97 chronically infected wounds in Tanzania, understanding the bacterial spectrum and factors

98 impairing effective treatment becomes imperative. This rationale rests significantly on the
99 pressing need to streamline antibiotic stewardship in Tanzania. In line with WHO's Global
100 Antimicrobial Resistance and Use Surveillance System (GLASS) goals, which aims to foster
101 standardized AMR data collection and analysis globally - this study contributes valuable
102 localized data; data which will inform and shape national strategies in the fight against AMR.
103 Given the lack of research on pre- and post-surgical chronic wound infections in the Tanga
104 region, this data aligns with the goals of both WHO and the Tanzania National Antimicrobial
105 Plan 2022-2028¹⁴.

106 Soaring infection rates within the surgical department is a critical health crisis that
107 reveals gaps in healthcare stewardship within the management and prescription of wound
108 infections. This Tanzanian research setting was vital to investigate the antimicrobial
109 susceptibility profiles of bacterial isolates in chronic wound infections. The study not only
110 fills existing knowledge gaps but also fosters informative practices where antimicrobial drugs
111 are used judiciously, effectively mitigating the impact of drug-resistant infections in Tanzania
112 and the East African region.

113 The research investigated the bacterial isolates and their antibiotic susceptibility
114 patterns in patients with chronically infected wounds in the surgical ward at Tanga Regional
115 Referral Hospital (TRRH). The study fulfilled the primary objective of identifying the
116 bacteria responsible for chronic wound infections and their resistance patterns.

117

118 **Materials and Methods**

119 **Study aim, design, and selection criteria**

120 This study employed a cross-sectional approach conducted from 30/10/2023 to
121 03/12/2023, at TRRH. Utilizing quantitative bacterial analysis, wound swab samples were
122 collected by the healthcare professionals in the surgical/obstetrics-gynecology, emergency,

123 and medical-pediatric wards, employing microscopy Gram stain and culture methods to
124 identify bacteria and their susceptibility patterns, facilitated through Pus Culture and
125 Sensitivity tests. The cross-sectional study focused on collecting and analyzing current data,
126 while the retrospective study reviewed past records to discern patterns and trends related to
127 wound infections.

128 The selection criteria focused on all admitted patients of all ages and sexes exhibiting
129 chronic wound infections, while excluding individuals who did not exhibit such conditions.
130 This criterion was chosen to provide insights into the bacteria characteristics and resistance
131 patterns prevalent in such clinical settings.

132

133 **Sample size and population**

134 The focal point of this study was the diverse group of patients admitted to TRRH with
135 chronic wounds. This population encapsulated both males and females, who have been
136 afflicted with chronic wound infections that have significantly affected their quality of life.
137 The following were the preliminary considerations used in deriving the sample size for the
138 quantitative study:

139 $N_0 = \square$ Sample size; $Z = \square$ Confidence level; $P = \square$ Estimated proportion of chronic wound infections in the
140 population; $E = \square$ Desired level of precision; $Z = \square 1.96$, $P = \square 0.8$ (80%), $E = \square 0.05$

$$N_0 = Z^2 \frac{P(1 - P)}{E^2}$$

$$N_0 = 1.96^2 \frac{0.8(1 - 0.8)}{0.05^2} = 3.842(0.8) \left(\frac{0.2}{0.0025} \right)$$

141 $N_0 = 246$ patients.

142 Accounting for a potential 10% loss to follow-up or refusal:

143 $0.10 \times 246 = 24.6$, approximately 25 patients.

144 Finite population correction (Hoyle, 2015):

$$n = N_o + \frac{N_o}{\left(\frac{N_o - 1}{N}\right)} + 1$$

145 n = Adjusted Sample size; N = Population size (100 patients);

$$n = \frac{271}{\left(\frac{271 - 1}{100}\right)} + 1$$

146

$$n = \frac{271}{3.7} = 73 \text{ patients}$$

147 Preliminary considerations estimated the sample size to be around 73 participants.

148 This estimation is based on trends observed in previous studies conducted in similar settings.

149 An 80% culture positivity rate for wounds was found in the previous three months (May

150 2023-July 2023) at TRRH. Therefore, the actual sample size was 87 patients for quantitative

151 analysis.

152

153 **Study setting**

154 The Tanga Regional Referral Hospital (TRRH), famously referred to as Bombo

155 Regional Hospital, is a significant healthcare facility located in Tanga, Tanzania. With a

156 history dating back to the German colonial era of the 1890s, the hospital was initially

157 established in response to the high mortality rate caused by malaria. On average, the hospital

158 admits 28 patients per month for chronic wound infections.

159

160 **Sampling strategy**

161 The study adopted a consecutive sampling strategy. All patients meeting the inclusion
162 criteria during the study period were approached for sample collection until the desired
163 sample size was achieved from 30/10/2023 to 03/12/2023.

164

165 **Ethical Statement**

166 Ethical approval for data collection for this study was obtained from the National
167 Health Research Ethics Review Committee (NatHREC) in Tanzania, valid from 27/10/2023
168 to 26/10/2024. The approval (reference: NIMR/HQ/R.8a/Vol.IX/4443) was granted for
169 conducting research on antimicrobial susceptibility profiles in patients with chronic wound
170 infections at Tanga Regional Referral Hospital. The study adhered to the ethical principles
171 outlined in the Belmont Report and the Declaration of Helsinki, and progress reports were
172 submitted to the Ministry of Health and the National Institute for Medical Research as per
173 NatHREC guidelines. This study was conducted as part of the ‘GLOH 3950 – Global Health
174 Practice and Research: An Experiential Learning Course’ at Georgetown University. Under
175 this framework, local IRB approval (NatHREC) was required and obtained, while
176 Georgetown IRB approval was not necessary for this research as per university policy. Head
177 of Surgery at Tanga Regional Referral Hospital, Dr. Rashid Suleiman, collaborated in the
178 study and granted permission for the work at the hospital level.

179 Retrospective data was collected from hospital medical records and laboratory reports
180 covering the period 01/07/2023 to 30/10/2023. This data was accessed and analyzed
181 between 30/10/2023 and 03/12/2023, following ethical approval. The data collection was
182 conducted collaboratively, with Dr. Victor Msengi (Tanga Regional Referral Hospital)
183 leading the process. Dr. Msengi anonymized all patient data before providing it to the
184 research team, ensuring that no identifying information was accessible to the authors during
185 or after data collection. The anonymized data included patient demographics, diagnoses,

186 treatment history, and bacterial isolate profiles. All data handling adhered to the ethical
187 requirements outlined by NatHREC to ensure patient confidentiality, and no attempts were
188 made to re-identify participants.

189 As for prospective data collection, participants were recruited from the Tanga
190 Regional Referral Hospital between 30/10/2023 and 03/12/2023. Eligible participants
191 included individuals with chronic wound infections who provided consent to participate in
192 the study. Written informed consent was obtained from all participants prior to inclusion in
193 the study. Consent forms were available in both English and Swahili to ensure
194 comprehension. The consent process was facilitated by Nurse Theresia Mtui, a native Swahili
195 speaker, who distributed and explained the consent forms to participants to ensure their full
196 understanding. No participants were recruited without written consent.

197 **Inclusivity in global research**

198 Additional information regarding the ethical, cultural, and scientific considerations
199 specific to inclusivity in global research is included in the Supporting Information.

200

201 **Data Collection Tools and Procedures**

202 **Primary cultures**

203 The primary goal of collecting pus samples from the wounds was to investigate the
204 antibacterial susceptibility of the isolates present in chronic wound infections. Before
205 collecting the pus sample, the wound sites were cleaned carefully to avoid contamination.
206 Trained hospital staff collected pus samples using sterilized swabs, ensuring the safe and
207 hygienic handling of samples. The collected samples were immediately transported to the
208 laboratory in a secure transport medium to prevent any alterations in the bacterial properties.
209 Upon receipt, swab specimens collected from the patients were systematically recorded,

210 marking the initiation of the laboratory investigation process. This step ensures traceability
211 and proper management of the sample data. Patient records were utilized to supplement the
212 swab test data, filling in missing variables and providing basic clinical information such as
213 age, gender, and clinical diagnosis. All patient information was handled in compliance with
214 privacy and data protection regulations.

215

216 **Antibacterial Susceptibility Testing**

217 Upon arrival to the laboratory, the samples underwent a Gram stain procedure to
218 categorize the bacteria into Gram-positive and Gram-negative groups. Examples of Gram-
219 positive bacteria include *Staphylococcus aureus* and *Streptococcus pneumoniae*, while
220 *Escherichia coli* and *Salmonella enterica* are examples of Gram-negative bacteria. The
221 samples were then cultured on Mueller-Hinton (MH) agar plates, setting the stage for the
222 Kirby-Bauer disk diffusion test. The research employed antibacterial susceptibility testing
223 using the discs recommended by the Clinical and Laboratory Standards Institute (CLSI)
224 guidelines¹⁵. The study targeted both aerobic and anaerobic bacteria, given the nature of
225 chronic wound infections, which can often be polymicrobial with both types present.

226 **Preparation:** 6-mm filter paper disks loaded with known concentrations of antimicrobial
227 compounds were placed on the inoculated MH agar plates.

228 **Incubation:** The plates were incubated at a controlled temperature of $35^{\circ}\text{C} \pm 2^{\circ}\text{C}$, facilitating
229 bacterial growth and antimicrobial diffusion simultaneously. This process helped in
230 establishing the zones of inhibition, where bacterial growth is curtailed by the antimicrobial
231 agent.

232 **Observation:** After 24 hours, the zone of inhibition around each disk were observed. This
233 zone size indicates susceptibility or resistance to the antimicrobial compound.

234 **Recording and Interpretation:** The zones of inhibition were measured, and based on the
235 zone size, the isolates were categorized as susceptible (S), intermediate (I), or resistant (R) to
236 the specific antimicrobial agents. This classification is done using a standardized
237 interpretation chart based on guidelines provided by the Kirby-Bauer Disk Diffusion
238 Susceptibility Test Protocol¹⁶ and TRRH's CLSI guidelines¹⁵.

239

240 **Reporting**

241 **Data compilation:** The data accumulated were meticulously recorded, documenting the
242 susceptibility patterns of the isolates. The findings were communicated back to the clinical
243 team, assisting them in making informed decisions regarding patient care and treatment
244 strategies.

245

246 **Data analysis**

247 Data analysis involved a comprehensive examination of the patterns of bacterial
248 susceptibility and resistance. Patient records were anonymized. Statistical software was
249 employed to analyze the data, focusing on the correlation between bacterial types, resistance
250 patterns, and patient demographics. Data analysis was primarily conducted using STATA
251 version 18. Microsoft Excel was employed for initial data organization and preliminary
252 analysis. Lastly, Python played a role in the data analysis process and data visualization. This
253 combination of STATA, Microsoft Excel, and Python provided a robust, multi-layered
254 approach to data analysis, ensuring both the reliability and depth of the findings.

255

256 **Results**

257 Of the 89 eligible patients, 82 had a positive wound culture (92.1%). 58.5% of these
258 patients were male and 41.5% female. Fig 1 shows the frequency of wound infections among
259 all age groups and sex, with a median age of 39 years and an overall range from 0-83 years.
260 The median age for females were 35 years, with an overall range from 1-75 years. The
261 median age for males were 39.5 years, with an overall range from 0-83 years. This suggests
262 that wound infections were most prevalent in middle-aged patients during the study period.
263 Most wounds were located at the lower limb, accounting for nearly 60% of all cases (n = 52).
264 Primary diagnoses are shown in Table 1, in which 20% are attributed to surgical-site
265 infections. However, these findings indicate a notable portion of records where wound
266 locations were not adequately recorded.

267

268 **Fig 1. Frequency of wound bacterial infections by age and sex at TRRH.**

269

270 **Table 1. Primary diagnoses of TRRH patients: July-November 2023 with Pus C&S**

271 **Tests.**

Primary Diagnosis	Percent
Surgical-Site Infection	20.9%
Diabetic Foot Ulcer	18.6%
Otitis Media	12.8%
Chronic Osteomyelitis	11.6%
Septic Wound	10.5%
Necrotizing Infections	8.2%

Not Recorded	5.8%
Abscess	3.5%
Urosepsis	3.5%
Pyomyositis	2.3%
Pyogenic Arthritis	2.3%

272

273 The majority of patients had a single bacterial isolate identified in their wound (Fig
274 2). 80.0% of the bacterial isolates consisted of either *S. aureus*, *Citrobacter spp*, *K.*
275 *pneumoniae*, *P. mirabilis*, *P. aeruginosa*, *E. coli* or *P. vulgaris* (Fig 2). Among the 13 distinct
276 species identified, *S. aureus* emerged as the most prevalent, constituting nearly 29.0% of the
277 isolates (n = 24). This prevalence underscores the significance of *S. aureus* in wound
278 infections due to its known pathogenicity, relevance in HAI and its potential impact on
279 treatment outcomes. *Citrobacter spp*, *P. mirabilis*, and *K. pneumoniae* are also notably
280 present, each accounting for approximately 9.0% to 14.0% of the isolates, reflecting their role
281 in clinical settings.

282

283 **Fig 2. Distribution of bacteria isolates identified from samples at TRRH.**

284

285 The Surgical Department accounted for a substantial majority of pus wound swabs
286 (54.0%), indicative of the nature of surgical procedures, where the risk of wound infections is
287 inherently higher due to invasive procedures and open wounds. The Emergency Medicine
288 Department (EMD) contributed 14 swabs, making up 16.6% of the total infections. The
289 urgency and varied nature of cases in emergency settings could explain this significant
290 proportion. This finding highlights the areas where wound-related complications are most
291 prevalent, guiding resource allocation and the focus of infection control initiatives.

292 The analysis of patient diagnoses indicated a substantial prevalence of comorbid
293 conditions. Nearly half of the patient cohort, approximately 46.0%, were documented with
294 multiple medical diagnoses, as opposed to a solitary primary condition. For the prevalent
295 diagnoses of patients with infections, SSI (20.9%) and diabetic foot ulcers (18.6%) were the
296 most common diagnoses, followed by otitis media (12.8%). Secondary and tertiary diagnoses
297 included conditions such as diabetes mellitus, hypertension, fractures, and cellulitis. This
298 highlights the variety of conditions leading to the need for such tests within the patient
299 population.

300 The analysis of antibiotic resistance patterns in the top five bacterial isolates; *S.*
301 *aureus*, *Citrobacter spp*, *K. pneumoniae*, *P. mirabilis*, and *P. aeruginosa*, (Fig 3) revealed a
302 concerning trend in MDR. In the analysis, focus was placed on *S. aureus* due to its unique
303 high resistance profile. Notably, amoxicillin was found to be almost universally ineffective,
304 resisting 100.0% of all tested bacteria except *S. aureus*, exemplifying its limitation in clinical
305 utility for this regional hospital. Similarly, cephalosporins such as ceftazidime, ceftriaxone,
306 and cefazolin exhibited high levels of resistance in *Citrobacter*, *K. pneumonia*, and *P.*
307 *mirabilis*, suggesting a widespread cephalosporin-resistant profile in these isolates.

308

309 **Fig 3. Antibiogram heatmap of resistance profiles of top five bacterial isolates at TRRH.**

310

311 *P. aeruginosa* had a unique pattern with complete resistance to several antibiotics,
312 including amoxicillin, tobramycin, and augmentin, while being entirely susceptible to others
313 like gentamycin, ciprofloxacin, and meropenem. This indicates a selective but profound AMR
314 characteristic of this pathogen. On the other hand, meropenem emerged as the most effective
315 antibiotic across the majority of the isolates, suggesting its potential as a first-line treatment
316 option.

317 The resistance data, when viewed through the lens of the tier system¹⁵, underscores
318 the necessity of strategic antibiotic selection in combating *S. aureus* infections. Tier 1
319 Antibiotics, considered primary for routine testing, showed varied effectiveness. For instance,
320 cefoxitin demonstrated significant resistance (47.1%), indicating a possible prevalence of
321 methicillin-resistant *S. aureus* (MRSA) in the isolate pool. Erythromycin exhibited an 85.7%
322 resistance rate, suggesting limited utility in treatment. While clindamycin (38.9% resistance)
323 might still be effective in certain clinical cases. The susceptibility of *S. aureus* to antibiotics
324 such as meropenem, cefazolin, and tobramycin highlights effective alternative options within
325 the local context of TRRH, especially for managing MDR strains. Additionally, the
326 effectiveness of less commonly used antibiotics like chloramphenicol and nalidixic acid
327 offers valuable insights for local antibiotic guidelines, particularly in resource-limited
328 settings, reflecting unique resistance dynamics shaped by regional prescribing practices and
329 bacterial exposure patterns in Tanga.

330 Tier 2 Antibiotics, used when Tier 1 antibiotics are not effective, like tetracycline
331 showed varying resistance (38.5%). This suggests this antibiotic could be effective in MRSA
332 cases. Other Tier 2, 3 and 4 antibiotics, reserved for high-risk MDR patients, did not appear
333 in TRRH laboratory testing but are crucial for consideration, given their role in treating *S.*
334 *aureus*.

335

336 Discussion

337 These findings, underscores the complexity inherent to the patient cases encountered
338 within the clinical setting. The implications of this data are manifold. First, it suggests that
339 patients present with multifaceted health challenges, which necessitate a nuanced approach to
340 treatment that extends beyond the scope of a single diagnosis. The coexistence of secondary
341 and tertiary diagnoses alongside primary conditions, such as diabetes paired with wound

342 infections, signals the need for integrated care pathways and a multidisciplinary approach to
343 healthcare delivery. Furthermore, the high incidence of additional diagnoses may also reflect
344 the interconnected nature of diseases, where one condition potentially predisposes individuals
345 to further health complications. This pattern highlights the importance of comprehensive
346 patient assessments to ensure that all underlying conditions are identified and addressed in
347 the treatment plan.

348 Similar to previous research findings, globally, this study's bacterial isolate profile
349 findings have significant overlaps. Previous research studies also found that *S. aureus*¹⁷ was
350 the most prevalent bacteria. This study documented *Citrobacter spp*, *Proteus mirabilis* and *K.*
351 *pneumoniae* as notable contributors to wound infections as well. *P. aeruginosa* was similar in
352 that it was one of the higher resistant isolates¹⁸. This study also found that meropenem was
353 effective in bacterial isolates¹⁹.

354 This study's results align with other studies^{20,21} done in Tanzania and Sierra Leone,
355 showing that high Extended Spectrum β -lactamase production among Gram-negative rods
356 contributes to widespread resistance, especially in *Citrobacter spp*, *K. pneumoniae*, and *P.*
357 *mirabilis*. There is a clear pattern of increasing resistance to commonly used antibiotics like
358 amoxicillin, cotrimoxazole, and cephalosporins in both studies. This trend raises concerns
359 about the overuse and accessibility of these drugs leading to escalated bacterial resistance.

360 The high levels of resistance to multiple antibiotics, particularly in *S. aureus*,
361 *Citrobacter spp*, *K. pneumoniae*, and *P. mirabilis*, are indicative of a burgeoning MDR crisis.
362 These findings underscore the urgency for tailored antibiotic stewardship and the
363 development of novel antimicrobial strategies. They also highlight the critical need for
364 ongoing surveillance and research into antibiotic resistance patterns, which is essential for
365 guiding effective clinical interventions and curbing the rise of MDR pathogens.

366 The overwhelming prevalence of swabs in the surgical department underlines the
367 need for robust infection control measures and efficient wound management strategies in
368 these departments. Moreover, fewer than 15.0% of swabs originated from outpatient settings.
369 This finding supports previous research indicating a greater incidence of infections among
370 inpatients as compared to outpatients¹⁸.

371 Compounding this concern is the prevalence of specific categories of infections
372 observed in this study. As noted previously, SSI were found to be the most prevalent at
373 20.9%, closely followed by diabetic foot ulcers at 18.6%, echoing findings from previous
374 research. For instance, Gosling²², identified HAI, particularly in surgical and orthopedic
375 wards, as one of the most frequent complications, accounting for 36.7% of cases in their
376 study titled '*Prevalence of hospital-acquired infections in a tertiary referral hospital in*
377 *northern Tanzania*'. This correlation suggests a persistent challenge in managing SSIs across
378 various healthcare settings. Another study's findings² on the high prevalence of polymicrobial
379 infections in diabetic wounds, particularly involving Gram-negative rods, complement this
380 research's findings on the high incidence of diabetic foot ulcers.

381 In addition to the focus on specific categories of infections, the analysis of patient
382 diagnoses in this study reveals a substantial prevalence of comorbid conditions. Nearly half
383 of the patient cohort (46.0%) were documented with multiple medical diagnoses. Similar
384 complexity has been noted in other studies, such as research on Tanzanian adults with
385 hypertension-related diseases who used herbal treatments. In this study, 81.2% of patients
386 presented with multiple health conditions²³. The parallel between these findings underlines
387 the multifaceted nature of patient health in hospital settings, where individuals often face
388 surgical complications and other comorbid conditions, necessitating a comprehensive and
389 integrated approach to healthcare.

390 The overconsumption of antibiotics and its heightened resistance also negatively
391 impacts the economy. With increased resistance, there is an elevated cost for more expensive
392 antibiotics, specialized equipment, longer hospital stays, and isolation procedures for
393 patients²⁴. Many patients are now resistant to first-line antimicrobials and must switch to
394 second or third-line options, imposing a considerable strain on healthcare systems. These
395 escalating costs might heighten the financial burden on individuals and communities,
396 potentially leading to increased healthcare inequities²⁵. This economic pressure could impede
397 progress in improving global health outcomes, making it imperative to address antibiotic
398 resistance with urgency and coordinated efforts across East Africa.

399

400 **Limitations**

401 The study encountered limitations in its sample selection, specifically focusing on
402 patients admitted to the hospital. This approach, by design, excluded the analysis of patients
403 outside the hospital setting, potentially introducing a bias to the findings. Future studies with
404 a more inclusive and diverse participant sample are recommended to ensure a more
405 comprehensive understanding. For bacterial analysis, collection of swab samples was
406 confined to patients with the financial means to afford the test costs. This financial barrier
407 resulted in a potential overlook of a more diverse spectrum of patients from various
408 socioeconomic backgrounds.

409 Another limitation was the unavailability of a full spectrum of antibiotics for testing
410 in the laboratory due to resource constraints. To maintain laboratory protocol, testing was
411 guided by Clinical and Laboratory Standards Institute (CLSI) guidelines, which recommend
412 specific antibiotics for different bacterial isolates, leading to some variability in the
413 antibiotics tested across samples. Future studies should secure sufficient funding to ensure

414 that testing costs are not a hindrance. By doing so, future research can provide a more
415 inclusive dataset, capturing a wider range of patient bacterial profiles and thereby enriching
416 the understanding of the subject matter. Moreover, while swabbing is a commonly used, non-
417 invasive, and cost-effective method for specimen collection, it does have inherent drawbacks.
418 Inadequate specimen collection has the potential to skew results. However, in this study, this
419 potential limitation was reduced by thoroughly cleansing the wound before swab collection,
420 thereby reducing the likelihood of such contamination.

421 Lastly, the small sample size limited the capacity to perform advanced statistical
422 analyses that could have enhanced the study's robustness. Regarding generalizability, the
423 findings provide localized data specific to TRRH rather than reflecting broader population
424 trends, which may limit external validity. Additionally, due to the study's limited resources,
425 the data does not differentiate between community-associated and healthcare-associated
426 infections. Limited information from healthcare providers about patients' prior antibiotic use,
427 particularly OTC purchases before seeking hospital care, further constrained additional
428 extrapolative analysis. This limitation complicates understanding the timing of antibiotic use,
429 as many patients potentially self-medicate prior to seeking professional care. Future studies
430 might address this by including community data and capturing antibiotic purchase histories to
431 improve the context of AMR patterns.

432

433 **Recommendations**

434 The high prevalence of inadequate care is deeply intertwined with broader social
435 determinants of health, including poverty, education, and social stratification. These factors
436 collectively play a pivotal role in shaping healthcare accessibility and quality. In light of these
437 findings, the study proposes two main recommendations. These recommendations are
438 designed to be practical and actionable, addressing the urgent needs identified in the research.

439 Their implementation possesses the potential to significantly improve patient outcomes,
440 alleviate the burden of AMR and enhance overall quality of healthcare delivery in the region.

441

442 **Strengthening surveillance on antibiotic resistance:**

443 Enhancing surveillance systems and research efforts is crucial for understanding and
444 monitoring the trends and patterns of antibiotic resistance. This would aid in developing
445 targeted strategies to mitigate the spread of MDR pathogens. This recommendation involves
446 expanding the capability of both hospital-based and community-based surveillance networks
447 to accurately track trends and patterns of antibiotic resistance. The logistics of this
448 enhancement would include equipping hospitals and community health centers with the
449 necessary technology and training staff to collect, analyze, and report data on antibiotic use
450 and resistance patterns. This data would provide a clearer picture of the resistance landscape,
451 enabling more targeted and effective interventions.

452 Another key element in this strategy is fostering collaboration between academic
453 institutions, healthcare facilities, and government health agencies. This collaborative effort
454 would focus on conducting in-depth research to understand the causes, mechanisms, and
455 spread of MDR. By pooling resources and expertise, these institutions can undertake more
456 comprehensive and sophisticated research projects. Such collaboration could involve sharing
457 samples, data, and research findings, as well as jointly applying for research grants and
458 funding. This cooperative approach would not only enhance the quality of the research, but
459 also expedite the process of gaining critical insights into antibiotic resistance.

460 Establishing a system for regular data sharing and reporting among healthcare
461 facilities and public health agencies is crucial. This system would facilitate a coordinated
462 response to MDR challenges by providing all stakeholders with timely and accurate
463 information. This could be achieved through the creation of a centralized database accessible

464 to relevant parties, where data on antibiotic use and resistance can be regularly updated and
465 analyzed. Regular meetings and conferences could also be organized to discuss findings,
466 share best practices, and coordinate efforts.

467 Based on the surveillance data and research findings, targeted public health
468 interventions can be implemented. These interventions might include infection control
469 measures in hospitals and public awareness campaigns about the importance of responsible
470 antibiotic use. Tailoring these interventions to specific communities based on the data
471 collected ensures that they are as effective as possible. Moreover, these interventions would
472 need to be dynamic, adapting to the evolving nature of antibiotic resistance.

473 As mentioned prior, the GLASS-AMR WHO action plan calls for nations to develop
474 standardized AMR data collection and analysis based on regional data. The findings from the
475 Tanga region study directly support this goal, offering insights that are region-specific and
476 therefore more relevant and actionable for local health authorities. The Tanzania National
477 Antimicrobial Plan 2022-2028 also emphasizes the need for localized research and data to
478 inform its strategies against AMR. This alignment significantly enhances the potential for
479 securing funding, as the study's objectives align with those of major global and national
480 health initiatives. Securing funding for the proposed enhancements in surveillance systems,
481 research collaborations, and public health interventions becomes more feasible when the
482 research is aligned with these larger global and national initiatives.

483 **Development of community-based health programs:**

484 Transitioning from the broader context of AMR to the more focused realm of wound
485 infection management, the development of community-based health programs emerges as a
486 crucial recommendation. These programs, aimed at early detection and management of
487 wound infections, should be made accessible and affordable to all patients, regardless of their
488 socioeconomic status. This accessibility can be facilitated through subsidies from government

489 or non-governmental organizations. The program would implement mobile clinics in rural
490 and underserved areas within Tanzania. These clinics will provide essential services such as
491 basic wound care, education on wound management, and early detection of potential
492 complications. Their mobility ensures that healthcare reaches those who are geographically
493 isolated or lack access to traditional healthcare facilities. Complementing mobile clinics,
494 regular health workshops in local communities are crucial. These workshops will serve as
495 platforms to educate residents about the importance of proper wound care and the role of
496 nutrition in the healing process. By raising awareness, these workshops can empower
497 individuals to take proactive steps in managing their health and seeking timely medical
498 intervention.

499 An integral part of this recommendation is the training and deployment of community
500 HCWs. This aspect is particularly crucial in light of the disparities in HCW knowledge
501 observed in the study. These HCWs, equipped with the necessary skills and knowledge, can
502 conduct home visits to patients who are immobile or lack access to healthcare facilities. Their
503 role extends beyond providing basic wound care; they are also educators and advisors to
504 patients and their families. They can impart crucial knowledge about wound management and
505 prevention strategies, ensuring that even the most vulnerable sections of the community have
506 access to healthcare information. These community health workers would act as a vital link
507 between the patients and the healthcare system. They can identify cases that require more
508 advanced medical attention and facilitate referrals to hospitals, ensuring that patients receive
509 comprehensive care.

510

511 **Conclusions**

512 The study emphasized the urgent challenge of AMR, especially among pathogens
513 such as *S. aureus*, *Citrobacter spp*, *K. pneumoniae*, and *P. mirabilis*. Addressing this issue

514 requires immediate action in antibiotic stewardship and the development of novel treatment
515 strategies. The study revealed significant MDR and high infection rates particularly in the
516 surgical ward. However, it also identifies opportunities for targeted interventions,
517 emphasizing the need for enhanced public health and healthcare worker education, improved
518 healthcare infrastructure, and integrated approaches that respect cultural contexts.

519 This study's unique contribution lies in its exploration of AMR at a Tanzanian
520 regional referral hospital, highlighting critical areas for intervention and improvement in
521 healthcare strategies. These insights are especially vital in settings where resource constraints
522 significantly influence health management. The recommendations proposed herein aim to
523 improve patient outcomes, reduce the burden of AMR, and enhance the overall quality of
524 healthcare delivery in the local context. In doing so, they contribute to the global effort in
525 managing and preventing chronic wound infections.

526 **Declarations**

527 **Ethics approval and consent to participate**

528 The proposed study is grounded in the ethical principles of beneficence, non-maleficence,
529 and respect for autonomy. The anticipated benefits of the study, which include enhancing
530 knowledge about chronic wound infections and potentially developing more effective
531 treatment strategies, justify the ethical conduct of the study. The study protocol was endorsed
532 through rigorous scientific ethical review by the National Institute of Medical Research
533 (NIMR) (ethical approval NIMR/HQ/R.8a/Vol. IX/4443 granted on 27/10/2023). All
534 participants signed a written informed consent prior to inclusion. All methods were
535 performed in accordance with the relevant guidelines and regulations.

536 **Consent for publication**

537 I hereby provide consent for the publication of the manuscript detailed above, including any
538 accompanying images or data contained within the manuscript.

539 **Availability of data and materials**

540 The datasets used and/or analysed during the current study are available in the Dryad
541 repository. The data can be accessed at the following

542 DOI: [http://datadryad.org/stash/share/o8XJQKJH7tVM6SnBA5wY0K9-
543 nV9S5VZc0MCY52h24V4](http://datadryad.org/stash/share/o8XJQKJH7tVM6SnBA5wY0K9-nV9S5VZc0MCY52h24V4).

544 **Competing interests**

545 The authors declare that they have no competing interests.

546 **Funding**

547 This research was funded by Georgetown University's Global Health Department.

548 **Authors' contributions**

549 Principal investigator: AD; Study design: AD, JPAL, VM; Data collection: TM, VM, AD;
550 Laboratory procedures: SS, TM; Data analysis: AD, JPAL; Approved hospital use: RS; wrote
551 draft of manuscript: AD; and reviewed and approved the final draft of the manuscripts: JPAL,
552 AD, VM, SS, TM, RS.

553 **Acknowledgments**

554 We thank all patients, laboratory scientists & medical microbiologists and medical staff at
555 Tanga Regional Referral Hospital, Tanzania and the Institute of Medical Research for their
556 assistance and continuous support.

557

558

References

- 559 [1] World Health Organization. Report signals increasing resistance to antibiotics in
560 bacterial infections in humans and need for better data. WHO 2022b.
561 <https://www.who.int/news/item/09>
- 562 [2] Kassam, N.A., Damian, D.J., Kajeguka, D. et al. Spectrum and antibiogram of
563 bacteria isolated from patients presenting with infected wounds in a Tertiary Hospital,
564 northern Tanzania. BMC Res Notes 2017; 10, 757. [https://doi.org/10.1186/s13104-](https://doi.org/10.1186/s13104-017-3092-9)
565 [017-3092-9](https://doi.org/10.1186/s13104-017-3092-9)
- 566 [3] Tikhomirov, E. WHO programme for the control of hospital infections.
567 Chemioterapia 1987; 6(3), 148–151.
- 568 [4] Mzee T, Kazimoto T, Madata J, et al. Prevalence, antimicrobial susceptibility and
569 genotypic characteristics of *Staphylococcus aureus* in Tanzania: a systematic
570 review. *Bull Natl Res Cent.* 2021;45:162. doi:10.1186/s42269-021-00612-z
- 571 [5] World Health Organization. Global priority list of antibiotic-resistant bacteria to
572 guide research, discovery, and development of new antibiotics. Geneva: WHO; 2017.
573
- 574 [6] Ventola C. L. The antibiotic resistance crisis: part 1: causes and threats. P & T
575 2015; 40(4), 277–283.
- 576 [7] Habboush Y, Guzman N. Antibiotic resistance. [Updated 2023 Jun 20]. In:
577 StatPearls. Treasure Island (FL): StatPearls Publishing; 2024
578 Jan. <https://www.ncbi.nlm.nih.gov/books/NBK513277/>

- 579 [8] Kunin C. M. Resistance to antimicrobial drugs--a worldwide calamity. Ann.
580 Intern. Med. 1993; 118(7), 557–561. [https://doi.org/10.7326/0003-4819-118-7-](https://doi.org/10.7326/0003-4819-118-7-199304010-00011)
581 [199304010-00011](https://doi.org/10.7326/0003-4819-118-7-199304010-00011)
- 582 [9] Goossens H. Antibiotic consumption and link to resistance. CMI: ESCMID 2009;
583 15 Suppl 3, 12–15. <https://doi.org/10.1111/j.1469-0691.2009.02725.x>
- 584 [10] Ayukekbong, J.A., Ntemgwa, M. & Atabe, A.N. The threat of antimicrobial
585 resistance in developing countries: causes and control strategies. Antimicrob Resist
586 Infect Control 2017; 6, 47. <https://doi.org/10.1186/s13756-017-0208-x>
- 587 [11] World Health Organization. Global antimicrobial resistance and use surveillance
588 system (GLASS) report: 2022a.
589 <https://www.who.int/publications/i/item/9789240062702>
- 590 [12] Wall S. Prevention of antibiotic resistance - an epidemiological scoping review to
591 identify research categories and knowledge gaps. GHA 2019; 12(1), 1756191.
592 <https://doi.org/10.1080/16549716.2020.1756191>
- 593 [13] Sangeda, R. Z., Saburi, H. A., Masatu, F. C., et. al. National antibiotics utilization
594 trends for human use in Tanzania from 2010 to 2016 inferred from Tanzania
595 medicines and medical devices authority importation data. Antibiotics 2021; (Basel,
596 Switzerland), 10(10), 1249. <https://doi.org/10.3390/antibiotics10101249>
- 597 [14] Ministry of Health, United Republic of Tanzania. The United Republic of
598 Tanzania National Action Plan on Antimicrobial Resistance 2023-2028. World Health
599 Organization; 2023. Available from: [https://cdn.who.int/media/docs/default-](https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-spc-npm/nap-library/the-united-republic-of-tanzania---national-action-plan-2023--2028.pdf?)
600 [source/antimicrobial-resistance/amr-spc-npm/nap-library/the-united-republic-of-](https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-spc-npm/nap-library/the-united-republic-of-tanzania---national-action-plan-2023--2028.pdf?)
601 [tanzania---national-action-plan-2023--2028.pdf?](https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-spc-npm/nap-library/the-united-republic-of-tanzania---national-action-plan-2023--2028.pdf?)

- 602 [15] CLSI Clinical & Laboratory Standards Institute. CLSI M100 performance
603 standards for antimicrobial susceptibility testing. 33rd ed. CLSI 2022.
604 <https://clsi.org/standards/products/microbiology/documents/m100/>
- 605 [16] Hudzicki, J. Kirby-Bauer Disk Diffusion Susceptibility Test Protocol. ASM
606 2009.
- 607 [17] Mnyambwa NP, Mahende C, Wilfred A, Sandi E, Mgina N, Lubinza C, et al.
608 Antibiotic susceptibility patterns of bacterial isolates from routine clinical specimens
609 from referral hospitals in Tanzania: a prospective hospital-based observational
610 study. *Infect Drug Resist.* 2021;14:869-878. doi:10.2147/IDR.S294575. PMID:
611 33688222; PMCID: PMC7937390.
- 612 [18] Dekker, D., Pankok, F., Thye, T., Taudien, S., Oppong, K., Akenten, et. al. Clonal
613 clusters, molecular resistance mechanisms and virulence factors of Gram-Negative
614 bacteria isolated from chronic wounds in Ghana. *Antibiotics* 2021; (Basel,
615 Switzerland), 10(3), 339. <https://doi.org/10.3390/antibiotics10030339>
- 616 [19] Agyepong, N., Govinden, U., Owusu-Ofori, A., & Essack, S. Y. Multidrug-
617 resistant gram-negative bacterial infections in a teaching hospital in Ghana.
618 *Antimicrob Resist Infect Control* 2018; 7, 37. [https://doi.org/10.1186/s13756-018-](https://doi.org/10.1186/s13756-018-0324-2)
619 [0324-2](https://doi.org/10.1186/s13756-018-0324-2)
- 620 [20] Mloka, D., Sangeda, R. Z., Mwambete, K. D., & Kamuhabwa, A. R. Magnitude
621 of Extended-Spectrum Beta-Lactamase-Producing Gram-Negative and Beta-
622 Lactamase-Producing Gram-Positive pathogens isolated from patients in Dar es
623 Salaam, Tanzania: A cross-sectional study. *Cureus* 2022; 14(4), e24451.
624 <https://doi.org/10.7759/cureus.24451>

- 625 [21] Schaumburg, F., Vas Nunes, J., Mönnink, G., Falama, A. M., Bangura, et. al.
626 Chronic wounds in Sierra Leone: pathogen spectrum and antimicrobial susceptibility.
627 Infection 2022; 50(4), 907–914. <https://doi.org/10.1007/s15010-022-01762-6>
- 628 [22] Gosling, R., Mbatia, R., Savage, A., Mulligan, J. A., & Reyburn, H. Prevalence
629 of hospital-acquired infections in a tertiary referral hospital in northern Tanzania. Ann
630 Trop Med Parasitol 2003; 97(1), 69–73. <https://doi.org/10.1179/000349803125002724>
- 631 [23] Liwa, A., Roediger, R., Jaka, H., et. al. Herbal and alternative medicine use in
632 Tanzanian adults admitted with hypertension-related diseases: A mixed-methods
633 study. Int. J. Hypertens 2017; Article 5692572. <https://doi.org/10.1155/2017/5692572>
- 634 [24] Prestinaci, F., Pezzotti, P., & Pantosti, A. Antimicrobial resistance: a global
635 multifaceted phenomenon. PGH 2015; 109(7), 309–318.
636 <https://doi.org/10.1179/2047773215Y.0000000030>
- 637 [25] Janssen, J., Afari-Asiedu, S., Monnier, A. et al. Exploring the economic impact of
638 inappropriate antibiotic use: the case of upper respiratory tract infections in Ghana.
639 Antimicrob Resist Infect Control 2022; 11, 53. [https://doi.org/10.1186/s13756-022-](https://doi.org/10.1186/s13756-022-01096-w)
640 [01096-w](https://doi.org/10.1186/s13756-022-01096-w)